CSL is committed to the manufacture of approximately 50 million doses of the AstraZeneca COVID-19 vaccine, Vaxzevria. Already over 20 million doses have been produced to protect Australians and those in the Asia Pacific region, and it is expected that the remaining production will be completed early next year.
As CSL Chair Brian McNamee AO said at the Annual General Meeting this week: “We are pleased to say that the Australian Government and AstraZeneca trusted us as their partners to help the country respond to the emerging crisis through the most effective solution available: vaccination.”
CSL and Seqirus are proud of the role they have played in providing Australia with onshore vaccine manufacturing capability throughout the pandemic.
/Public Release. View in full .
